2026年1月16日，陈影从旧金山飞回上海，飞机上坐满了中国创新药企的创始人、高管、投资者，大部分人看上去心情不错，他们刚参加完全球规模最大的 医疗健康盛会——摩根大通医疗健康大会（下称"JPM"）。 这是陈影第一次参加JPM。2025年10月，她所在的赛默罗生物收到了几家跨国药企的邀请，希望能在JPM期间洽谈合作。赛默罗生物有一款原始创新（first- in-class）药物已进入临床二期试验，并获得美国食品药品监督管理局（FDA）的孤儿药认定，这引起了跨国药企的兴趣。 陈影此行与五六家跨国公司进行了一对一会谈，奔波在会场、各大洽谈室之间，每天睡觉不超过5小时。许多参会者都有类似体验，赫吉亚生物创始人崔坤 元开玩笑说，参会最直接的收获是"比较累"。大家期望在四天的日程里尽可能捕捉最前沿的行业信息、与意向合作方深入沟通。 多位受访者对经济观察报表示，相比前几年，2026年JPM带来的正向预期更明显。尤其是对中国创新药企，几乎每家跨国公司都不掩饰对中国资产的兴趣。 经济观察报 记者 张英 他观察到，尽管FDA官员在JPM期间提及了中美创新药竞争，但并未强调保护主义政策，更多提及的是美国医院、FDA如何优化临床试 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Ascentage Pharma Group International presented its achievements in 2025 and outlined its global innovation strategy for 2026 at the J.P. Morgan Healthcare Conference [1][2] Company Overview - Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer [9] - The company has a diverse pipeline that includes inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [9] Milestone Achievements - In 2025, Ascentage Pharma accelerated its global expansion, advancing product commercialization, clinical development, and pipeline innovation [2] - The company has established a strong foundation for sustained growth through its innovative engine in hematologic malignancies and solid tumors [2] Product Development - The two core products, Olverembatinib (a third-generation BCR-ABL inhibitor) and Lisaftoclax (a Bcl-2 inhibitor), are key growth drivers for 2026 [3] - Both products have shown significant progress in 2025 and are expected to generate a "dual-engine" effect for future growth [3] Clinical Studies and Innovations - Ascentage Pharma has made advancements in multiple clinical studies for its key drug candidates, presenting data at international academic congresses [4] - The company received IND clearance from the U.S. FDA for APG-3288, a novel BTK degrader, marking a significant step in targeted degradation [4][5] Pipeline Progress - The company is advancing several key clinical programs, including APG-5918 (EED inhibitor) and APG-2449 (FAK/ALK/ROS1 inhibitor), which are in various stages of clinical trials [6][7] - Multiple global registrational Phase III trials are progressing rapidly for its key products [5] Future Outlook - Potential milestones for 2026 include ongoing investigations of Olverembatinib, Lisaftoclax, and other pipeline candidates, which have not yet received FDA approval [8] - The company aims to continue its growth in commercial sales and expand patient accessibility across hospitals in China [12]

Market Overview - U.S. stocks showed mixed performance, with the Dow Jones index declining approximately 0.2% on Wednesday [1] Company Highlights - Monte Rosa Therapeutics Inc (NASDAQ:GLUE) experienced a significant increase in share price, rising 45.2% to $23.25 after announcing interim data from a Phase 1 clinical study for MRT-8102 [1] - Ventyx Biosciences Inc (NASDAQ:VTYX) shares surged 37.5% to $13.82 following reports of advanced acquisition talks with Eli Lilly & Co. (NYSE:LLY) for over $1 billion [2] - Neumora Therapeutics Inc (NASDAQ:NMRA) saw a rise of 24.7% to $2.27 [2] - Regencell Bioscience Holdings Ltd (NASDAQ:RGC) increased by 21.1% to $40.00 [2] - Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25, with Piper Sandler initiating coverage with an Overweight rating and a price target of $5 [2] - Anywhere Real Estate Inc (NYSE:HOUS) gained 15.6% to $16.71 [2] - AXT Inc (NASDAQ:AXTI) increased by 13.8% to $22.96 [2] - Immuneering Corp (NASDAQ:IMRX) rose 13.1% to $7.60 [2] - Compass Therapeutics Inc. (NASDAQ:CMPX) gained 13.1% to $5.56 [2] - MBX Biosciences Inc (NASDAQ:MBX) rose 11.2% to $31.90 [2] - Rezolve AI PLC (NASDAQ:RZLV) increased by 10.8% to $3.36 [2] - United Microelectronics Corp (NYSE:UMC) gained 10.4% to $8.96 after reporting sales growth for December and the full year [2] - PBF Energy Inc (NYSE:PBF) rose 9.2% to $29.73 [2] - Navan Inc (NASDAQ:NAVN) increased by 8.3% to $18.42 [2] - Ascentage Pharma Group International (NASDAQ:AAPG) gained 8.3% to $28.17 after announcing IND clearance for BTK Degrader APG-3288 by the U.S. FDA [2] - Intel Corp (NASDAQ:INTC) rose 6.4% to $42.60 as the company is enhancing its gaming strategy by developing a new chip for handheld gaming devices [2]

Core Viewpoint - Ascentage Pharma has received IND clearance from the U.S. FDA for its next-generation BTK-targeted protein degrader, APG-3288, which will enter clinical studies for patients with relapsed/refractory B-cell malignancies, marking a significant expansion of the company's innovative pipeline [1][7]. Company Overview - Ascentage Pharma Group International is a global, commercial stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [11]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [11]. Product Development - APG-3288 is the first highly potent and selective BTK degrader developed using Ascentage Pharma's proprietary PROTAC technology, designed to induce proteasome-mediated degradation of the BTK target [4]. - The drug aims to overcome resistance associated with existing BTK inhibitors by blocking the BCR-BTK signaling axis at its source, providing a novel therapeutic strategy [4][6]. Clinical Study - A global, multicenter, open-label Phase I study will evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies [2][7]. - Preclinical studies have shown that APG-3288 demonstrates more potent BTK degradation and higher selectivity compared to other BTK degraders in development [5]. Strategic Importance - The FDA clearance for APG-3288 represents a major milestone for Ascentage Pharma, validating its innovative design capabilities and strategic pipeline expansion in the field of hematologic malignancies [6]. - The company plans to accelerate the global clinical development of APG-3288 and explore its combinatory potential with existing proprietary small-molecule agents [6].

Group 1 - The core viewpoint of the article highlights the steady recovery of global capital markets in 2025, with US stock markets continuing to be a key platform for Chinese companies seeking cross-border financing, despite a notable structural differentiation in the number and scale of listings [3][17] - In 2025, a total of 93 Chinese companies successfully listed on US stock markets through various methods, marking a 7.8% increase from 64 companies in 2024, with 149 additional companies having publicly submitted applications for US listings, indicating strong future momentum [3][17] - The traditional IPO remains the dominant listing method, with 90.3% of the successful listings (84 out of 93) being through IPOs, while De-SPAC and OTC transfers accounted for 8.6% and 1.1% respectively, showcasing a clear preference for IPOs among Chinese companies [4][17] Group 2 - The fundraising characteristics of Chinese companies in the US IPO market are marked by a concentration of capital, with the top three companies (Smithfield, Bawang Chaji, and Yasheng Pharmaceutical) accounting for 33.9% of the total $2.822 billion raised, while over half (58.3%) of the companies raised less than $10 million [11][17] - The industry distribution of companies going public in the US is diverse, with significant representation from application software, traditional industries like construction and manufacturing, and modern service sectors such as pharmaceuticals and logistics, reflecting the dynamic nature of China's economic transformation [14][17] - The average listing cycle for Chinese companies in the US has improved, with an average duration of approximately 198 days and a median of 185 days, indicating enhanced efficiency in the listing process [16][17] Group 3 - The Nasdaq remains the most attractive exchange for Chinese companies, with 82 out of 93 companies choosing to list there, while one company opted for the NYSE and another for the AMEX, demonstrating the exchange's strong appeal for cross-border financing [8][17] - The structural characteristics of the 2025 US listings reflect the resilience and vitality of Chinese companies in their internationalization efforts, with a focus on compliance and strategic alignment with regulatory environments being crucial for future listings [17]

行业分布多元，应用软件等科技企业领跑，建筑、工业等传统行业稳健跟进，制药、餐饮物流等现代服 务业活力凸显，全面映射中国经济转型的蓬勃动力。 2025年截至年末，93家中企成功登陆美股，149家公开递交上市申请。与2024年的69家相比，上市数量 保持了温和增长。 交易所选择上，纳斯达克延续绝对优势，89家企业在此挂牌，占比达96%，仅4家选择纽交所。 适用企业：新兴科技公司，盈利模式尚未完全验证寻求更快上市速度的企业估值模型特殊，需要更灵活 定价机制的公司 1家企业通过OTC转板上市，Tianci International Inc（CIIT）从OTC市场成功转板到纳斯达克，该路径更 多适用于已在OTC市场积累一定流动性与估值基础的企业。 实施路径：先在OTC市场挂牌交易，建立交易历史和股东基础满足主板上市条件后申请转板获得批准后 正式在纳斯达克或纽交所交易。 优势：前期成本和门槛相对较低为中小企业提供渐进式成长路径转板成功通常能带来流动性和估值提 升。 展望2026年，随着纳斯达克新规生效（净收入标准门槛提升200%），传统IPO的门槛进一步提高，中小 企业OTC转板有望迎来更大发展机遇，值得注意的事，从O ...

12月22日，格隆汇在线上举办"科技赋能·资本破局"分享会。本次分享会，备受瞩目的卓越公司评选榜单将隆重揭晓，其中格隆汇"金格奖"年度卓越公司评选 中，百利天恒(688506.SH)、东阳光药(06887.HK)、东曜药业-B(01875.HK)、和铂医药-B(02142.HK)、华领医药-B(02552.HK)、先声药业(02096.HK)、亚盛 医药(06855.HK/AAPG.US)、真实生物8家企业荣获"年度卓越生物医药企业"奖项。（排名不分先后，按公司首部字母顺序排列） "年度卓越生物医药企业"是从技术创新、研发实力、成果转化等多方面综合评估，旨在表彰在生物医药领域具有自主核心技术、持续创新并能高效将科研成 果转化为临床或商业应用的领军企业。本次评选通过定量数据分析和专家评审团等方式得出最终结果。 格隆汇以"全球视野，下注中国"为初衷，本次评选旨在打造出投资圈中最具参考价值的上市公司及独角兽公司排行榜。此次"金格奖"上市公司评选覆盖港交 所、上交所、深交所、纽交所、美国证券交易所、纳斯达克证券交易所挂牌上市的全部上市公司及独角兽公司。 ...

"年度卓越生物医药企业"是从技术创新、研发实力、成果转化等多方面综合评估，旨在表彰在生物医药领域具有自主核心技术、持续创新并能高效将科研成 果转化为临床或商业应用的领军企业。本次评选通过定量数据分析和专家评审团等方式得出最终结果。 格隆汇以"全球视野，下注中国"为初衷，本次评选旨在打造出投资圈中最具参考价值的上市公司及独角兽公司排行榜。此次"金格奖"上市公司评选覆盖港交 所、上交所、深交所、纽交所、美国证券交易所、纳斯达克证券交易所挂牌上市的全部上市公司及独角兽公司。 12月22日，格隆汇在线上举办"科技赋能·资本破局"分享会。本次分享会，备受瞩目的卓越公司评选榜单将隆重揭晓，其中格隆汇"金格奖"年度卓越公司评选 中，百利天恒(688506.SH)、东阳光药(06887.HK)、东曜药业-B(01875.HK)、和铂医药-B(02142.HK)、华领医药-B(02552.HK)、先声药业(02096.HK)、亚盛 医药(06855.HK/AAPG.US)、真实生物8家企业荣获"年度卓越生物医药企业"奖项。（排名不分先后，按公司首部字母顺序排列） ...

ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. T ...